"Cicada" COVID Variant Found in 29 US States — What the CDC Report and Vaccine Data Actually Show

A formal CDC report published March 19 confirmed the BA.3.2 COVID subvariant — known informally as "Cicada" — in 25 US states, three major airports, and multiple clinical cases. Wastewater surveillance data published in the week since has expanded the footprint further: as of March 28, the variant has been detected in wastewater systems across 29 states, according to data from The Conversation citing Stanford's WasteWaterSCAN programme.

The findings come alongside new data on how current vaccines perform against BA.3.2 — data that has been widely reported but, in many cases, without enough context to interpret clearly.

What the CDC MMWR report found

The CDC's Morbidity and Mortality Weekly Report (MMWR), published March 19, covers BA.3.2 detections worldwide through February 11, 2026. It is the most comprehensive official summary of BA.3.2 published to date.

Key findings from the report: BA.3.2 was detected in 23 countries across Africa, Asia, Europe, North America, and Oceania. In the United States, the variant was found in wastewater samples from 25 states and in airplane wastewater collected at San Francisco International Airport, JFK, and Washington Dulles. The first US clinical specimen was collected January 5, 2026.

The report documented a small number of US clinical cases, including two in hospitalised older adults with underlying conditions and one in a young child treated as an outpatient. All recovered. The CDC explicitly noted that these cases "do not necessarily indicate the variant causes more severe disease" — the hospitalised patients had pre-existing conditions that independently increase COVID risk.

The wastewater signal is growing

Wastewater surveillance has become the most consistent signal for BA.3.2 in the US, given the steep decline in clinical sequencing since 2023. For the week ending March 21, BA.3.2 was detected in 11% of national wastewater samples monitored by the CDC's National Wastewater Surveillance System (NWSS). By March 28, Stanford's WasteWaterSCAN programme reported detections in 29 states.

Wastewater data captures a broader and less biased signal than clinical sequencing, which now skews heavily toward hospitalised and symptomatic cases. A wastewater detection does not mean the variant is causing illness at that level — it means the variant is present in the community and detectable in sewage. It is an early indicator, not a count of sick people.

What the vaccine data actually shows

BA.3.2 carries 70 to 75 mutations in its spike protein compared to earlier Omicron variants — significantly more than recent variants. Because current 2025-26 vaccines were designed targeting JN.1 and LP.8.1, laboratory studies have shown reduced neutralisation of BA.3.2 by vaccine-generated antibodies. This has been described in some coverage as "immune escape."

What this means in practice: the antibodies produced by current vaccines are less effective at blocking BA.3.2 infection than they were at blocking earlier variants. This is a lab measurement, not a clinical outcome measure. It does not mean vaccines provide no protection.

Public health experts, including those cited by PBS NewsHour and CIDRAP, have consistently said that current vaccines are still expected to provide meaningful protection against severe disease and death from BA.3.2. T-cell immunity — which is harder to measure but critical for preventing severe illness — is less affected by spike protein mutations than antibody responses. No country has yet reported a statistically significant increase in severe disease or mortality attributable to BA.3.2.

No new emergency measures anywhere

As of March 29, no country has issued travel advisories, mask mandates, or emergency health declarations in connection with BA.3.2. No WHO emergency committee has been convened. The variant remains classified as a Variant Under Monitoring — the lowest of three monitoring tiers. No reclassification to Variant of Interest or Variant of Concern has been made.

State health departments in the US are monitoring the variant. Michigan health officials described the US as "vulnerable" given reduced vaccination rates and lower recent COVID immunity in the population — a reference to population-level immunity context, not a warning about variant severity.

Long COVID remains a consideration

A review published in The Conversation on March 28 noted that long COVID continues to occur in approximately 3 in 100 COVID infections, based on current data. This figure is not specific to BA.3.2 — it reflects the general rate across recent Omicron-lineage infections. No BA.3.2-specific long COVID data has been published.

Where the variant stands globally

The variant has now been confirmed in 23 countries. In Europe, Denmark, Germany, and the Netherlands are reporting the highest sequence shares — approximately 30% of recent sequences in those countries, according to data cited by multiple sources. Japan, Hong Kong, and South Korea remain the highest-share countries in Asia. The global picture reflects both genuine spread and the uneven distribution of sequencing capacity: countries with more sequencing infrastructure report detections earlier and with more precision.

BA.3.2 was first identified in South Africa in November 2024 and first detected in a US traveller in June 2025. Its reappearance after the BA.3 lineage went dormant for nearly three years — since early 2022 — is the origin of the "Cicada" nickname.